Status: Recruiting
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
Participants needed: 180
Trial details
Phase: Phase 3Age: 3-23Biological sex: AllType: InterventionalSponsor: Organon and CoUpdated: Jun 4, 2026Locations: 47
Eligibility criteria
Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 mont... [+3]
Significant neurological disorder or history of seizure [+9]